1 Guidance

1 Guidance

This guidance was developed using the single technology appraisal (STA) process.

1.1 Ipilimumab is recommended, within its marketing authorisation, as an option for treating adults with previously untreated advanced (unresectable or metastatic) melanoma, only if the manufacturer provides ipilimumab with the discount agreed in the patient access scheme.

  • National Institute for Health and Care Excellence (NICE)